Risk for respiratory complications in patients with type 2 diabetes not increased with use of GLP1 receptor agonists<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, April 25, 2024 (HealthDay News) — The risk for postoperative respiratory complications is similar among patients undergoing emergency surgery regardless of preoperative glucagon-like peptide 1 receptor agonist (GLP-1 RA) use, according to a research letter published online April 22 in the\u00a0Journal of the American Medical Association<\/em>.<\/p>\n Anjali A. Dixit, M.D., M.P.H., from Stanford University in California, and colleagues used a claims database to evaluate the risk for postoperative respiratory complications among patients with type 2 diabetes and a prescription fill for GLP-1 RAs who underwent one of 13 emergency surgeries. The analysis included data identified from the Merative MarketScan Commercial Database (2015 through 2021).<\/p>\n The researchers found that among 23,679 patients with diabetes and emergency surgery, 14.8 percent had a GLP-1 RA fill. A GLP-1 RA fill was associated with a greater likelihood of being male, using more antidiabetic agents, and having diagnoses of obesity. The overall incidence of postoperative respiratory complications was similar for those with a GLP-1 RA fill and those without (3.5 versus 4.0 percent; odds ratio, 0.85; 95 percent confidence interval, 0.70 to 1.04). Findings were similar in an adjusted analysis (odds ratio, 1.03; 95 percent confidence interval, 0.82 to 1.29).<\/p>\n “Results of this study suggest that liberalizing the withholding guidelines for GLP-1 RAs preoperatively should be considered,” the authors write.<\/p>\n Abstract\/Full Text\u00a0(subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n